|Mr. Derek J. Maetzold||Founder, CEO, Pres & Director||1.36M||N/A||1962|
|Mr. Frank Stokes||CFO & Treasurer||803.01k||N/A||1970|
|Ms. Kristen M. Oelschlager R.N., RN||Chief Operating Officer||724.6k||N/A||1968|
|Mr. Toby W. Juvenal||Chief Commercial Officer||724.6k||N/A||1961|
|Camilla Zuckero||Exec. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Alice Bahner Izzo||Sr. VP of Marketing||N/A||N/A||N/A|
|Ms. Keli Greenberg||VP of HR & Exec. Director of HR||N/A||N/A||N/A|
|Dr. Robert W. Cook Ph.D.||Sr. VP of R&D||N/A||N/A||1972|
|Mr. Bernhard E. Spiess||Company Sec.||N/A||N/A||1960|
|Mr. John W. Abbott||VP & Controller||N/A||N/A||N/A|
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc.’s ISS governance QualityScore as of 1 November 2022 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 8; Compensation: 10.